Trial pipeline
Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.
Free access · No subscription for research tools or data exports
Filter the development pipeline
4 trials match this view; 4 reported facilities; 4 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.
Enrollment sum: 97 across 4 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.
Recorded study-start years
Current indexed registry status
Reported research conditions
Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.
Milestones to investigate
The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.
For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.
Matching trial records
| Trial | Sponsor and phase | Status | Enrollment | Start / primary completion / completion | Research workflow |
|---|---|---|---|---|---|
| Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleMethamphetamine Use Disorder · Substance-Related Disorders · Chemically-Induced Disorders · Substance Use Disorders · Stimulant-Use Disorder | University of Wisconsin, Madison PHASE1 | Terminated Registry updated 2026-05-12 | 5 ACTUAL | 2023-03-03 2024-03-07 2024-03-07 | |
| A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineMethamphetamine Use Disorder | Kevin Murnane EARLY_PHASE1 | Recruiting Registry updated 2025-10-07 | 20 ESTIMATED | 2025-04-04 2027-03 2027-03 | |
| Psilocybin Recovery Intervention for Stopping Methamphetamine UseMethamphetamine Use Disorder · Human Immunodeficiency Virus (HIV) | Nicky Mehtani, MD, MPH PHASE2 | Recruiting Registry updated 2026-11-09 | 30 ESTIMATED | 2026-12 2029-04 2029-06 | |
| Psilocybin in the Treatment of Methamphetamine Use DisorderMethamphetamine Use Disorder | Peter Hendricks PHASE2 | Not yet recruiting Registry updated 2026-09-21 | 42 ESTIMATED | 2027-02-01 2032-02-01 2032-02-01 |
Reported research facilities
LSU Health ShreveportShreveport, Louisiana, United States · Coordinates available
UCSF at Zuckerberg San Francisco General HospitalSan Francisco, California, United States · Coordinates available
University of Alabama at BirminghamBirmingham, Alabama, United States · Coordinates available
University of WisconsinMadison, Wisconsin, United States · Coordinates available
This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.